Loading
Liver Disease Diagnosis and Treatment / Liver Diseases and Immunity · Journal article
Frontiers in Gastroenterology · August 13, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes current understanding of how estrogen deficiency during menopause, combined with obesity, may promote MASH progression through molecular, metabolic, and inflammatory mechanisms. The review identifies diagnostic approaches and emerging pharmacologic therapies but does not present new empirical evidence or clinical trial results to support or quantify these relationships.
Narrative review. Women with metabolic dysfunction-associated steatotic liver disease or steatohepatitis, particularly postmenopausal women with obesity.
Estrogen deficiency contributes to metabolic dysregulation through impaired insulin signaling, increased visceral adiposity, lipotoxicity, oxidative stress, and adipose tissue inflammation Emerging pharmacologic therapies including glucagon-like peptide-1 receptor agonists, tirzepatide, and resmetirom demonstrate promising metabolic and hepatic benefits Non-invasive diagnostic modalities including serum biomarkers, transient elastography, CAP, and MRI-PDFF have improved disease detection and risk stratification
Estrogen deficiency contributes to metabolic dysregulation through impaired insulin signaling, increased visceral adiposity, lipotoxicity, oxidative stress, and adipose tissue inflammation Emerging pharmacologic therapies including glucagon-like peptide-1 receptor agonists, tirzepatide, and resmetirom demonstrate promising metabolic and hepatic benefits
This review highlights sex-specific mechanisms in MASH progression during menopause and identifies diagnostic and therapeutic avenues for investigation. Clinicians should recognize that emerging pharmacologic options and personalized approaches may be beneficial in postmenopausal women, but evidence from prospective trials is needed to establish their efficacy and optimal use.
This is a narrative review synthesizing mechanistic pathways and existing evidence rather than presenting original clinical data or trial results, raising questions about the menopause-obesity-MASH axis rather than answering them with new evidence.
As stated by the source record.
This review highlights sex-specific mechanisms in MASH progression during menopause and identifies diagnostic and therapeutic avenues for investigation. Clinicians should recognize that emerging pharmacologic options and personalized approaches may be beneficial in postmenopausal women, but evidence from prospective trials is needed to establish their efficacy and optimal use.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) have emerged as major global health challenges, particularly among individuals with obesity and metabolic dysfunction. Menopause represents a critical hormonal transition characterized by estrogen deficiency, visceral adiposity, insulin resistance, and chronic low-grade inflammation, all of which may accelerate MASH progression and hepatic fibrosis in women. This narrative review summarizes current evidence regarding the menopause-obesity axis in MASH progression, focusing on molecular mechanisms, histopathological alterations, diagnostic biomarkers, imaging modalities, and emerging therapeutic strategies. Estrogen deficiency contributes to metabolic dysregulation through impaired insulin signaling, increased visceral adiposity, lipotoxicity, oxidative stress, and adipose tissue inflammation, thereby promoting hepatic steatosis and progression toward fibrosis. Histopathological progression is characterized by steatosis, hepatocyte ballooning, chronic inflammation, and extracellular matrix deposition. Non-invasive diagnostic approaches, including serum biomarkers, transient elastography, controlled attenuation parameter (CAP), and magnetic resonance imaging proton density fat fraction (MRI-PDFF), have improved disease detection and risk stratification. Lifestyle modification and sustained weight reduction remain the cornerstone of management, while emerging pharmacologic therapies such as glucagon-like peptide-1 receptor agonists, tirzepatide, and resmetirom demonstrate promising metabolic and hepatic benefits. Hormone-based and anti-fibrotic therapies may offer additional therapeutic potential in postmenopausal women with obesity-associated MASH. Collectively, the menopause-obesity axis appears to play a central role in hepatic injury and fibrosis progression through interconnected hormonal, metabolic, and inflammatory pathways. Improved understanding of sex-specific mechanisms may facilitate the development of personalized diagnostic and therapeutic approaches for postmenopausal women with MASLD and MASH.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.